Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz,

Slides:

Advertisements

Similar presentations

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

Advertisements

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance.

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization by Margit Schraders, Rolph Pfundt,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Characterization and quantification of clonal heterogeneity among hematopoietic stem cells: a model-based approach by Ingo Roeder, Katrin Horn, Hans-Bernd.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk.

Darwinian evolution and tiding clones in multiple myeloma

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Thomas A. Paul, Juraj Bies, Donald Small, and Linda Wolff

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Epigenetic heterogeneity is associated with genetic heterogeneity in CLL samples. Epigenetic heterogeneity is associated with genetic heterogeneity in.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma by Carmen Choi, Mathias Witzens, Marianna.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs and 1q21 amplification.

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

by Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, Maria G

Q-Q plot of observed P values against theoretical P values for factor analysis (red dots) and single gene–based methods (in blue). Q-Q plot of observed.

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions by Priyanka Pandey, Waseem Q. Anani,

Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53 by Bridget K. Marcellino, Ronald Hoffman, Joseph.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad F

BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1–positive B-cell acute lymphoblastic leukemia by Karen A. Dun, Rob Vanhaeften, Tracey J.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Volume 2(Supplement 1):1-3

Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications by Daria V. Babushok, Jamie L. Duke,

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk.

Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR by Duncan Murray, Jack Luke McMurray,

Plasma biomarker concentrations between study groups.

Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified by Maja Ludvigsen, Martin.

Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing by Aishwarya Iyer, Dylan Hennessey,

A population-based longitudinal study on the implication of demographic changes on blood donation and transfusion demand by Andreas Greinacher, Kerstin.

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

by Giovanni Palladini, and Giampaolo Merlini

Changes throughout time in the lineage content of clones regenerated in secondary mice. Changes throughout time in the lineage content of clones regenerated.

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth by Alexandra C. Sundermann, Keith Saum, Kelsey.

PD-L1 and tumor-associated macrophages in de novo DLBCL

by Sumita Ratnasingam, Patricia A. Walker, Huy Tran, Zane S

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Impact of age on clinical risk scores in follicular lymphoma

by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R

Comparison of variant associations from previous reports and results from the KP GWAS meta-analysis for 105 known prostate cancer risk SNPs. Plotted values.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Volume 2(Supplement 1):4-7

Presentation transcript:

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, Martin Granzow, Korbinian Hoffmann, Alwin Krämer, Marc-Steffen Raab, Jens Hillengass, Anja Seckinger, Christoph Kimmich, Tobias Dittrich, Carsten Müller-Tidow, Dirk Hose, Hartmut Goldschmidt, Ute Hegenbart, Anna Jauch, and Stefan O. Schönland BloodAdv Volume 2(20):2607-2618 October 23, 2018 © 2018 by The American Society of Hematology

Tilmann Bochtler et al. Blood Adv 2018;2:2607-2618 © 2018 by The American Society of Hematology

Subclone frequencies depending on disease and plasma cell stage. Subclone frequencies depending on disease and plasma cell stage. Subclone frequencies for patients with main clone and subclone within a single chromosome (green); pure subclone aberrations, where subclone and main clone affect different chromosomes (red); and both of these types for each disease entity (blue). P value is given for test on overall difference in subclone frequency between PC-AL and PC–non-AL accounting for stage of plasma cell dyscrasia. Tilmann Bochtler et al. Blood Adv 2018;2:2607-2618 © 2018 by The American Society of Hematology

Subclone frequencies specified for individual chromosomes. Subclone frequencies specified for individual chromosomes. Frequency of cytogenetic aberrations, sorted by main clone (blue), main clone plus subclone within a single chromosome (green), and subclone (red) by disease entity and stage. P values denote a significant trend of increased or decreased overall frequency of the respective cytogenetic aberration in the PC-AL or PC–non-AL group, respectively. Only P values significant (P ≤ .05) after adjustment for multiple testing are provided. *P value for deletion of 17p refers to a shift in the subclone/main clone ratio along the progression of plasma cell dyscrasia (P = .013 before adjustment; P = .15 after adjustment for multiple testing). Tilmann Bochtler et al. Blood Adv 2018;2:2607-2618 © 2018 by The American Society of Hematology

Multivariate analysis of factors influencing subclone formation. Multivariate analysis of factors influencing subclone formation. Multivariate analysis of factors influencing subclone formation in a forest plot, both for PC-AL and PC–non-AL separately as well as combined. In both the PC-AL group and PC–non-AL control group, t(11;14) as main clone aberration was associated with decreased subclone formation, whereas hyperdiploidy was associated with increased subclone formation in the PC–non-AL control group. The effects were similar in the PC-AL and non–PC-AL groups, suggesting that subclone formation is an inherent trait of the respective cytogenetic aberrations, irrespective of clinical disease. Tilmann Bochtler et al. Blood Adv 2018;2:2607-2618 © 2018 by The American Society of Hematology